$MLTX
MoonLake Immunotherapeutics Stock $mltx

$mltx Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000182158623000007 Filed on March 20, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.327M	$23.01M	$2.224M
YoY Change	139.51%	403.52%
% of Gross Profit
Research & Development	$11.37M	$42.05M	$4.990M
YoY Change	127.84%	18.35%
% of Gross Profit
Depreciation & Amortization	$3.290K	$12.36K	$0.00
YoY Change		148.65%
% of Gross Profit
Operating Expenses	$16.70M	$65.06M	$2.224M
YoY Change	650.65%	1323.55%	2107.48%
Operating Profit		-$65.06M
YoY Change
Interest Expense			$2.260K
YoY Change			-84.85%
% of Operating Profit
Other Income/Expense, Net	$239.5K	$591.7K	-$40.00K
YoY Change	-698.78%	-1056.72%
Pretax Income	-$16.46M	-$64.47M	-$2.222M
YoY Change	640.63%	1319.21%	2488.55%
Income Tax	$11.01K	$36.37K	$0.00
% Of Pretax Income
Net Earnings	-$1.935M	-$49.97M	-$2.222M
YoY Change	-12.91%	1000.09%	2488.55%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.70
Diluted Earnings Per Share	-$0.05	-$1.70	-$150.1K
COMMON SHARES
Basic Shares Outstanding		29.36M shares
Diluted Shares Outstanding		29.36M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$72.11M	$72.11M	$666.8K
YoY Change	10713.84%	10715.21%	-50.09%
Cash & Equivalents	$39.51M	$39.51M	$8.039M
Short-Term Investments	$32.60M	$32.61M	$0.00
Other Short-Term Assets	$213.4K	$213.4K	$126.9K
YoY Change	68.11%	68.11%	-55.16%
Inventory
Prepaid Expenses	$4.179M		$1.449M
Receivables
Other Receivables	$217.1K		$148.8K
Total Short-Term Assets	$76.51M	$76.51M	$9.637M
YoY Change	693.96%	9539.71%	495.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$49.39K	$332.0K	$45.74K
YoY Change	7.98%	625.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments			$115.0M
YoY Change			0.02%
Other Assets
YoY Change
Total Long-Term Assets	$332.0K	$332.0K	$45.74K
YoY Change	625.79%	-99.71%	-99.96%
TOTAL ASSETS
Total Short-Term Assets	$76.51M	$76.51M	$9.637M
Total Long-Term Assets	$332.0K	$332.0K	$45.74K
Total Assets	$76.84M	$76.84M	$9.682M
YoY Change	693.63%	-33.66%	-91.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$138.2K	$138.2K
YoY Change		-90.33%
Accrued Expenses	$7.410M	$7.410M	$3.870M
YoY Change	91.47%	91.47%	5666.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$15.00M
YoY Change	-100.0%		25735.34%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.665M	$7.665M	$21.09M
YoY Change	-63.65%	98.06%	16745.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$411.2K	$411.2K	$4.025M
YoY Change	-89.78%	-89.78%	0.0%
Total Long-Term Liabilities	$411.2K	$411.2K	$239.9K
YoY Change	71.42%	-89.78%	-94.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.665M	$7.665M	$21.09M
Total Long-Term Liabilities	$411.2K	$411.2K	$239.9K
Total Liabilities	$8.077M	$27.95M	$21.33M
YoY Change	-62.13%	253.95%	413.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$80.65M		-$53.64M
YoY Change	50.34%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$0.00		$6.202K
YoY Change	-100.0%
Treasury Stock Shares			1.943M shares
Shareholders Equity	$48.90M	$48.90M	-$11.65M
YoY Change
Total Liabilities & Shareholders Equity	$76.84M	$76.84M	$9.682M
YoY Change	693.63%	-33.66%	-91.7%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$1.935M	-$49.97M	-$2.222M
YoY Change	-12.91%	1000.09%	2488.55%
Depreciation, Depletion And Amortization	$3.290K	$12.36K	$0.00
YoY Change		148.65%
Cash From Operating Activities	-$11.60M	-$55.89M	-$362.0K
YoY Change	3103.66%	9046.89%	14.29%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$16.01K	$20.00K
YoY Change	-100.0%	-68.43%
Acquisitions
YoY Change
Other Investing Activities	$9.901M	-$32.32M
YoY Change
Cash From Investing Activities	$9.901M	-$32.34M	-$20.00K
YoY Change	-49607.2%		-99.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.800K	$119.7M	0.000
YoY Change		-206253.52%	-100.0%
NET CHANGE
Cash From Operating Activities	-11.60M	-$55.89M	-362.0K
Cash From Investing Activities	9.901M	-$32.34M	-20.00K
Cash From Financing Activities	3.800K	$119.7M	0.000
Net Change In Cash	-1.691M	$31.47M	-362.0K
YoY Change	367.11%		-127.09%
FREE CASH FLOW
Cash From Operating Activities	-$11.60M	-$55.89M	-$362.0K
Capital Expenditures	$0.00	$16.01K	$20.00K
Free Cash Flow	-$11.60M	-$55.91M	-$382.0K
YoY Change	2935.91%	8348.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.001
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001821586
CY2022	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost Credit Excluding Service Cost Statement Of Income Or Comprehensive Income Extensible List DefinedBenefitPlanNetPeriodicBenefitCostCreditExcludingServiceCostStatementOfIncomeOrComprehensiveIncomeExtensibleList	http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	33720000	usd
CY2022	dei	Auditor Firm AuditorFirmId	23
CY2022	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2022	dei	Auditor Location AuditorLocation	Mountain View, CA
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39505627	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8038845	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32609108	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	217129	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	148774	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1449096	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	76511332	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	9636715	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	282580	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	49389	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45739	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	331969	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	45739	usd
CY2022Q4	us-gaap	Assets Assets	76843301	usd
CY2021Q4	us-gaap	Assets Assets	9682454	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2021Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1569290	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153629	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	0	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	15000000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4518311	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7665446	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21087601	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	128951	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	282206	usd
CY2021Q4	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	239860	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	411157	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	239860	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8076603	usd
CY2021Q4	us-gaap	Liabilities Liabilities	21327461	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	1942837	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	0	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	6202	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	129192291	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42061984	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80650212	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53643615	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	350946	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-168177	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48898296	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-11645007	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	19868402	usd
CY2021Q4	us-gaap	Minority Interest MinorityInterest	0	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	68766698	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	76843301	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9682454	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42048954	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35529331	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23012463	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18047681	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	65061417	usd
	us-gaap	Operating Expenses OperatingExpenses	53577012	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65061417	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-53577012	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	591732	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-61848	usd
CY2022	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-64469685	usd
	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-53638860	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4755	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-14532802	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	390753	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	269893	usd
	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-168177	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	660646	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-168177	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-63845405	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-53811792	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49437461	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53811792	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-14407944	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	0	usd
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106507	usd
	mnlk	Stock Issued During Period Shares Reverse Recapitalization StockIssuedDuringPeriodSharesReverseRecapitalization	3330231	shares
	mnlk	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	4851000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	495050	usd
	mnlk	Adjustments To Additional Paid In Capital Emission Fee Reimbursement AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement	4894	usd
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	19207697	shares
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	279364	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	27659237	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	9056299	usd
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1942837	shares
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	6202	usd
	us-gaap	Profit Loss ProfitLoss	-53643615	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-168177	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-11645007	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	134653204	usd
CY2022	mnlk	Adjustments To Additional Paid In Capital Emission Fee Reimbursement AdjustmentsToAdditionalPaidInCapitalEmissionFeeReimbursement	-56240	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	9658568	usd
	us-gaap	Profit Loss ProfitLoss	-53643615	usd
	us-gaap	Depreciation Depreciation	4971	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9052909	usd
CY2022	mnlk	Research And Development In Process Share Based Portion ResearchAndDevelopmentInProcessShareBasedPortion	0	usd
	mnlk	Research And Development In Process Share Based Portion ResearchAndDevelopmentInProcessShareBasedPortion	4851000	usd
CY2022	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	304031	usd
	us-gaap	Pension Expense Reversal Of Expense Noncash PensionExpenseReversalOfExpenseNoncash	71685	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-68454	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3635	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	68355	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	148774	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1449096	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1569290	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2685576	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-55893900	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	42226021	usd
CY2022	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	9901437	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16009	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32340593	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	28159181	usd
CY2022	mnlk	Proceeds From Reverse Recapitalization ProceedsFromReverseRecapitalization	134646009	usd
CY2022	mnlk	Proceeds From Contribution From Par Value Of Common Stock ProceedsFromContributionFromParValueOfCommonStock	42935	usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	15000000	usd
	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	0	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	usd
	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	6202	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3791	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3390	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	119692735	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43262876	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8540	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1873	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31466782	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8038845	usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39505627	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8038845	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4312	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	435005	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134700000	usd
CY2022Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	15000000.0	usd
CY2022Q2	mnlk	Investments Acquired Through Reverse Recapitalization InvestmentsAcquiredThroughReverseRecapitalization	115051000	usd
CY2022Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	80842000	usd
CY2022Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	116000000	usd
CY2022Q2	mnlk	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	15520000	usd
CY2022Q2	mnlk	Reverse Recapitalization Accrued Expenses ReverseRecapitalizationAccruedExpenses	5798000	usd
CY2022Q2	mnlk	Reverse Recapitalization Deferred Initial Public Offering Underwriting Fees ReverseRecapitalizationDeferredInitialPublicOfferingUnderwritingFees	4025000	usd
CY2022Q2	mnlk	Reverse Recapitalization Other Transaction Expenses ReverseRecapitalizationOtherTransactionExpenses	5697000	usd
CY2022Q2	mnlk	Reverse Recapitalization Net ReverseRecapitalizationNet	134689000	usd
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52701111	shares
CY2022Q2	mnlk	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	33.638698
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses. The significant judgments, estimates and assumptions relevant to the Company relate to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining whether the in-process research and development expenditure (“IPR&D”) has an alternative future use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the fair value of the portion of the aggregate purchase price relating to its own shares in connection with the acquisition of the in-license agreement;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">determining assumptions used in determining the fair value of share-based compensation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the recoverability of the deferred tax asset; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimating the amount of accruals in connection with the completion of clinical trial milestones.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:0.36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its judgments and estimates on various factors and information, which may include, but are not limited to, the Company’s forecasts and future plans, current economic conditions and observable market-based transactions of its own shares, the results of which form the basis for making judgments about the carrying value of assets and liabilities and recorded amounts of expenses that are not readily apparent from other sources. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future results of operation may be affected.</span></div>
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	100000	chf
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-59660	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-64500000	usd
CY2022Q4	mnlk	Current Assets In Excess Of Current Liabilities CurrentAssetsInExcessOfCurrentLiabilities	68800000	usd
CY2022Q4	us-gaap	Cash Cash	39500000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	32600000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	52490507	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	52099754	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	390753	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	52490507	usd
CY2022Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	2443863	usd
CY2021Q4	mnlk	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	547586	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1416597	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	23141	usd
CY2022Q4	mnlk	Prepaid Other Consulting And Advisory Services PrepaidOtherConsultingAndAdvisoryServices	105651	usd
CY2021Q4	mnlk	Prepaid Other Consulting And Advisory Services PrepaidOtherConsultingAndAdvisoryServices	31930	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	213357	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	846439	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4179468	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1449096	usd
CY2022Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	65979	usd
CY2021Q4	mnlk	Supply And Manufacturing Fees Payable Current SupplyAndManufacturingFeesPayableCurrent	183298	usd
CY2022Q4	mnlk	Other Accrued Consulting And Advisory Fees Current OtherAccruedConsultingAndAdvisoryFeesCurrent	51658	usd
CY2021Q4	mnlk	Other Accrued Consulting And Advisory Fees Current OtherAccruedConsultingAndAdvisoryFeesCurrent	71938	usd
CY2022Q4	mnlk	Accrued Legal And Intellectual Property Advisory Fees Payable Current AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent	40532	usd
CY2021Q4	mnlk	Accrued Legal And Intellectual Property Advisory Fees Payable Current AccruedLegalAndIntellectualPropertyAdvisoryFeesPayableCurrent	1233070	usd
CY2022Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	31687	usd
CY2021Q4	mnlk	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	50088	usd
CY2022Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	65116	usd
CY2021Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	30896	usd
CY2022Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	254972	usd
CY2021Q4	mnlk	Trade And Other Payables Current TradeAndOtherPayablesCurrent	1569290	usd
CY2022Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	5803432	usd
CY2021Q4	mnlk	Accrued Research And Development Services And License Fees Current AccruedResearchAndDevelopmentServicesAndLicenseFeesCurrent	2055687	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1109734	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1419137	usd
CY2022Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	218021	usd
CY2021Q4	mnlk	Accrued Consulting And Other Fees Current AccruedConsultingAndOtherFeesCurrent	49211	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	109826	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	63922	usd
CY2022Q4	mnlk	Accrued Legal Fees Current AccruedLegalFeesCurrent	15832	usd
CY2021Q4	mnlk	Accrued Legal Fees Current AccruedLegalFeesCurrent	930354	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7256845	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	4518311	usd
CY2021Q3	mnlk	Operating Lease Area Of Leased Space OperatingLeaseAreaOfLeasedSpace	2300	sqft
CY2021Q3	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P3Y
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.008
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	284717	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2137	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	282580	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153629	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	128951	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	200000	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	435005	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	435005	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1322874	usd
CY2020Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	0	usd
CY2022	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	138243	usd
CY2021	us-gaap	Defined Benefit Plan Benefit Obligation Contributions By Plan Participant DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant	64954	usd
CY2022	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	374317	usd
CY2021	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-174012	usd
CY2022	mnlk	Defined Benefit Plan Benefit Obligation Increase Decrease For Transfers DefinedBenefitPlanBenefitObligationIncreaseDecreaseForTransfers	-204695	usd
CY2021	mnlk	Defined Benefit Plan Benefit Obligation Increase Decrease For Transfers DefinedBenefitPlanBenefitObligationIncreaseDecreaseForTransfers	931257	usd
CY2022	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	16267	usd
CY2021	us-gaap	Defined Benefit Plan Foreign Currency Exchange Rate Changes Benefit Obligation DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation	-9184	usd
CY2022Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1321969	usd
CY2021Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1322874	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1083014	usd
CY2020Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	usd
CY2022	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	15522	usd
CY2021	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	5835	usd
CY2022	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	-115877	usd
CY2021	mnlk	Defined Benefit Plan Plan Assets Increase Decrease For Return Above Expected Returns DefinedBenefitPlanPlanAssetsIncreaseDecreaseForReturnAboveExpectedReturns	0	usd
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	138243	usd
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	73448	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	138243	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Contributions By Plan Participant DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant	64954	usd
CY2022	us-gaap	Defined Benefit Plan Assets Transferred To From Plan DefinedBenefitPlanAssetsTransferredToFromPlan	-204695	usd
CY2021	us-gaap	Defined Benefit Plan Assets Transferred To From Plan DefinedBenefitPlanAssetsTransferredToFromPlan	931257	usd
CY2022	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	-14687	usd
CY2021	us-gaap	Defined Benefit Plan Plan Assets Foreign Currency Translation Gain Loss DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss	7520	usd
CY2022Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1039763	usd
CY2021Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	1083014	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1039763	usd
CY2021Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1083014	usd
CY2022Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	1321969	usd
CY2021Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent	1322874	usd
CY2022Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-282206	usd
CY2021Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-239860	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-168177	usd
CY2020Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	0	usd
CY2022	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	268076	usd
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-168177	usd
CY2022	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-1817	usd
CY2021	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	0	usd
CY2022Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	101716	usd
CY2021Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-168177	usd
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0220
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate	0.0040
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0380
CY2021Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Expected Return On Plan Assets DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationExpectedReturnOnPlanAssets	0.0150
CY2022Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0180
CY2021Q4	mnlk	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Inflation DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfInflation	0.0110
CY2022Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0230
CY2021Q4	us-gaap	Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Rate Of Compensation Increase DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease	0.0160
CY2022	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	451075	usd
CY2021Q4	mnlk	Shares Authorized SharesAuthorized	36000000	shares
CY2021Q4	us-gaap	Shares Issued SharesIssued	33099402	shares
CY2022	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	1177354	shares
CY2022	mnlk	Stock Authorized During Period Shares Acquisitions StockAuthorizedDuringPeriodSharesAcquisitions	600000000	shares
CY2022	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	18424355	shares
CY2022Q4	mnlk	Shares Authorized SharesAuthorized	600000000	shares
CY2022Q4	us-gaap	Shares Issued SharesIssued	52701111	shares
	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.109
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.014
	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.010
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-49973249	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53643615	usd
	us-gaap	Net Income Loss NetIncomeLoss	-53643615	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29361353	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29361353	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7840707	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7840707	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7840707	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7840707	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.84
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.84
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.84
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9700000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9654778	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9052909	usd
CY2022	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2022	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.005
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2022	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
CY2022	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Numerator Enterprise ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationNumeratorEnterprise	360000000	usd
	mnlk	Share Based Compensation Arrangement By Share Based Payment Award Estimated Grant Date Fair Value Calculation Denominator Fully Diluted Shares ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedGrantDateFairValueCalculationDenominatorFullyDilutedShares	1070196	shares
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-62115251	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-53663726	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-2354434	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	24866	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64469685	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53638860	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.119
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0.001
	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.100
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4492435	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2963340	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	33451	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	8497	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	7210383	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2873281	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11736269	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5845118	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11736269	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5845118	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	11700000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	11700000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	60800000	usd
CY2022Q4	mnlk	Unrecognized Commitments And Contingencies UnrecognizedCommitmentsAndContingencies	31900000	usd

Files In Submission

Name	View Source	Status
0001821586-23-000007-index-headers.html	Edgar Link	pending
0001821586-23-000007-index.html	Edgar Link	pending
0001821586-23-000007.txt	Edgar Link	pending
0001821586-23-000007-xbrl.zip	Edgar Link	pending
consentofindependentregist.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mltx_2022q4xex311dasilva.htm	Edgar Link	pending
mltx_2022q4xex312bodenstedt.htm	Edgar Link	pending
mltx_2022q4xex321dasilva.htm	Edgar Link	pending
mltx_2022q4xex322bodenstedt.htm	Edgar Link	pending
mltx_ex1025forformxformofs.htm	Edgar Link	pending
mltx_ex41tofy2022formxdesc.htm	Edgar Link	pending
mnlk-20221231.htm	Edgar Link	pending
mnlk-20221231.xsd	Edgar Link	pending
mnlk-20221231_g1.jpg	Edgar Link	pending
mnlk-20221231_g2.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
mnlk-20221231_def.xml	Edgar Link	unprocessable
mnlk-20221231_lab.xml	Edgar Link	unprocessable
mnlk-20221231_pre.xml	Edgar Link	unprocessable
mnlk-20221231_htm.xml	Edgar Link	completed
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mnlk-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLTX
MoonLake Immunotherapeutics Stock $mltx

2022 Q4 Form 10-K Financial Statement

#000182158623000007 Filed on March 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX MoonLake Immunotherapeutics Stock $mltx

2022 Q4 Form 10-K Financial Statement

#000182158623000007 Filed on March 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLTX
MoonLake Immunotherapeutics Stock $mltx